

## **Update Hormonersatz: Bioidentische Hormongaben sind risikoarm.**

A. Römmler ZS Orthomol Med 2007; 2, S16-21

1. Bakken K, Alsaker E, Eggen AE, Lund E. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. *Int J Cancer*. 2004 Oct 20;112(1):130-4.
2. Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet*. 2003 Aug 9;362(9382):419-27.
3. Beral V, Bull D, Reeves G. Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. *Lancet*. 2005 Apr 30-May 6;365(9470):1543-51.
4. Brincat MP. Hormone replacement therapy and the skin. *Maturitas*. 2000 May 29;35(2):107-17.
5. Campagnoli C, Clavel-Chapelon F, Kaaks R et al. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. *J Steroid Biochem Mol Biol*. 2005 Jul;96(2):95-108.
6. Canonico M, Straczek C, Oger E et al. Postmenopausal hormone therapy and cardiovascular disease: An overview of main findings. *Maturitas*. 2006 Jul 20;54(4):372-9.
7. Chen WY, Manson JE, Hankinson SE et al. Unopposed estrogen therapy and the risk of invasive breast cancer. *Arch Intern Med*. 2006 May 8;166(9):1027-32.
8. Clavel-Chapelon F, Fournier A: E3N-EPIC cohort Update. Abstracts, 11th World Congress on the Menopause, Buenos Aires, Okt. 2005.
9. Csizmadi I, Collet JP, Benedetti A et al. The effects of transdermal and oral oestrogen replacement therapy on colorectal cancer risk in postmenopausal women. *Br J Cancer* 2004 Jan;90(1):76-81.
10. De Lignieres B, Dennerstein L, Backstrom T. Influence of route of progesterone metabolism. *Maturitas* 1995;21:251-57.
11. De Lignieres B, de Vathaire F, Fournier S et al. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. *Climacteric*. 2002 Dec;5(4): 332-40.
12. Den Tonkelaar I, Oddens BJ. Determinants of long-term hormone replacement therapy and reasons for early discontinuation. *Obstet Gynecol*. 2000 Apr;95(4):507-12.
13. Dennison EM, Arden NK, Kellingray S et al. Hormone replacement therapy, other reproductive variables and symptomatic hip osteoarthritis in elderly white women: a case-control study. *Br J Rheumatol*. 1998 Nov;37(11):1198-202.
14. Dupont A, Dupont P, Cusan L et al. Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women. *Maturitas* 1991 Oct;13(4):297-311.
15. Fabre A, Fournier A, Mesrine S et al. Oral progestagens before menopause and breast cancer risk. *Br J Cancer*. 2007 Feb 13.
16. Foidart JM, Colin C, Denoo X et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. *Fertil Steril*. 1998 May;69(5):963-9.
17. Fournier A, Berrino F, Riboli E et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. *Int J Cancer*. 2005 Apr 10;114(3):448-54.
18. Grodstein F, Lifford K, Resnick NM, Curhan GC. Postmenopausal hormone therapy and risk of developing urinary incontinence. *Obstet Gynecol*. 2004 Feb;103(2):254-60.
19. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. *J Womens Health (Larchmt)*. 2006 Jan;15(1):35-44.
20. Harvey PJ, Morris BL, Miller JA, Floras JS. Estradiol induces discordant angiotensin and blood pressure responses to orthostasis in healthy postmenopausal women. *Hypertension*. 2005 Mar;45(3):399-405.
21. Hendrix SL, Cochrane BB, Nygaard IE et al. Effects of estrogen with and without progestin on urinary incontinence. *JAMA*. 2005 Feb 23;293(8):935-48.
22. Ho SM. Estrogen, progesterone and epithelial ovarian cancer. *Reprod Biol Endocrinol*. 2003 Oct 07;1(1):73-81.
23. Huber JC. Hormonveränderungen im Alter: Genitale und extragenitale Auswirkungen. *Gynäkologe*. 1996;29: 726-34.

24. Kirsh V, Kreiger N. Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada. *Cancer Causes Control*. 2002 Aug;13(6):583-90.
25. Kovari E, Gold G, Herrmann FR et al. Cortical microinfarcts and demyelination significantly affect cognition in brain aging. *Stroke*. 2004 Feb;35(2):410-4.
26. Lauritzen C. Die präventive Estrogen-Gestagen-Langzeitsubstitution. *Frauenarzt*. 2001;42(11), 1230-67.
27. Le Gal G, Gourlet V, Hogrel P et al. Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study. *Atherosclerosis*. 2003 Jan;166(1):163-70.
28. Leake R. Contents of HRT and mechanisms of action. *J Epidemiol Biostat*. 1999;4(3):129-33.
29. Leo JC, Wang SM, Guo CH et al. Gene regulation profile reveals consistent anticancer properties of progesterone in hormone-independent breast cancer cells transfected with progesterone receptor. *Int J Cancer*. 2005 Nov 20;117(4):561-8.
30. Micheli A, Muti P, Secreto G et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. *Int J Cancer*. 2004 Nov 1;112(2):312-8.
31. Mosekilde L, Beck-Nielsen H, Sorensen OH et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study. *Maturitas*. 2000 Oct 31;36(3):181-93.
32. Moskowitz D. A comprehensive review of the safety and efficacy of bioidentical hormones for the management of menopause and related health risks. *Altern Med Rev*. 2006 Sept;11(3):208-223.
33. Nelson HD, Humphrey LL, Nygren P et al. Postmenopausal hormone replacement therapy: Scientific review. *JAMA*. 2002 Aug 21;288(7):872-81.
34. Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. *Steroids*. 1996 Apr;61(4):166-71.
35. O'Sullivan AJ, Crampton LJ, Freund J, Ho KKY. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. *J Clin Invest* 1998, 102:1035-1040.
36. Ohlinger R, Klein GM, Köhler G et al. Altersverteilung bei Patientinnen mit Mammatumoren in Abhängigkeit vom histologischen Befund. *Gyn* 2006;11:110-16.
37. PEPI-Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. *JAMA*. 1996 Feb 7;275(5):370-5.
38. Plu-Bureau G, Le MG, Thalabard JC et al. Percutaneous progesterone use and risk of breast cancer: results from a French cohort study of premenopausal women with benign breast disease. *Cancer Detect Prev*. 1999;23(4):290-6.
39. Rabe T, Geithövel F, Hadji P et al. Hormonersatztherapie – Nutzen und Risiken. *J Reproduktionsmed Endokrinol* 2006; 3(3):155-65.
40. Raine-Fenning NJ, Brincat MP, Muscat-Baron Y. Skin aging and menopause: implications for treatment. *Am J Clin Dermatol*. 2003;4(6):371-8.
41. Ridker PM, Rifai N, Rose L et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events *N Engl J Med*. 2002 Nov 14;347(20):1557-65.
42. Römmler A. Paradigmenwechsel bei der Substitution mit Östrogenen. *ZS Orthomol Med* 2003;3:13-17.
43. Römmler A. Neubewertung der HRT: Orale versus transdermale Östrogene sowie Progestagene versus Progesteron - Wege zur Risikoreduktion. In: Wolf A, Römmler A, Moltz L, Klentze M (Hrsg). *Anti Aging Medizin 2003*, congress compact verlag Berlin. 2004; 168-94.
44. Römmler A. Die Wahrheit über Hormone. SüdWest München, 2006.
45. Römmler A. Endokrinologische Aspekte der Anti-Aging-Medizin. *CME Praktische Fortbildung Gynäkologie, Geburtsmedizin, Gynäkologische Endokrinologie* 2006; 3, 18-34.
46. Römmler A. Wege zur risikoarmen HRT: Bioidentischer Hormonersatz. *J Preventive medicine* 2007, im Druck.
47. Rossouw JE, Anderson GL, Prentice RL et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women:

- principal results From the Women's Health Initiative randomized controlled trial. *JAMA*. 2002 Jul 17;288(3):321-33.
48. Rylance PB, Brincat M, Lafferty K et al. Natural progesterone and antihypertensive action. *Br Med J (Clin Res Ed)*. 1985 Jan 5;290(6461):13-4.
  49. Salpeter SR, Walsh JM, Greyber E et al. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. *J Gen Intern Med*. 2004 Jul;19(7):791-804.
  50. Scarabin PY, Oger E, Plu-Bureau G. EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. *Lancet*. 2003 Aug 9;362(9382):428-32.
  51. Scarabin PY et al. Abstracts, 11th World Congress on the Menopause, Buenos Aires, Okt. 2005.
  52. Schuback B. Die ältere Patientin im Brennpunkt der gynäkologischen Onkologie – demografische Entwicklung. *Gyn* 2006;11:451-55.
  53. Schumacher M, Guennoun R, Robert F et al. Local synthesis and dual actions of progesterone in the nervous system: neuroprotection and myelination. *Growth Horm IGF Res*. 2004 Jun;14 Suppl A:S18-33.
  54. Stahlberg C, Pedersen AT, Lynge E et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. *Int J Cancer*. 2004 May 1;109(5):721-7.
  55. Stefanick ML, Anderson GL, Margolis KL et al. WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. *JAMA*. 2006 Apr 12;295(14):1647-57.
  56. Stephenson K, Price C, Kurdowska A et al. Progesterone cream does not increase thrombotic and inflammatory factors in postmenopausal women. *Blood* 2004; 104,16.
  57. Straczek C, Oger E, Yon de Jonage-Canonico MB et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. *Circulation*. 2005 Nov 29;112(22):3495-500.
  58. Tollan A, Oian P, Kjeldsen SE et al. Progesterone reduces sympathetic tone without changing blood pressure or fluid balance in men. *Gynecol Obstet Invest*. 1993;36(4):234-8.
  59. Tsuda K, Kinoshita Y, Nishio I. Synergistic role of progesterone and nitric oxide in the regulation of membrane fluidity of erythrocytes in humans: an electron paramagnetic resonance investigation. *Am J Hypertens*. 2002 Aug;15(8):702-8.
  60. Vassilev V, Pretto CM, Cornet PB et al. Response of matrix metalloproteinases and tissue inhibitors of metalloproteinases messenger ribonucleic acids to ovarian steroids in human endometrial explants mimics their gene- and phase-specific differential control in vivo. *J Clin Endocrinol Metab*. 2005 Oct;90(10):5848-57.
  61. Von Muhlen D, Morton D, Von Muhlen CA, Barrett-Connor E. Postmenopausal estrogen and increased risk of clinical osteoarthritis at the hip, hand, and knee in older women. *J Womens Health Gend Based Med*. 2002 Jul-Aug;11(6):511-8.
  62. Vongpatanasin W, Tuncel M, Wang Z et al. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. *J Am Coll Cardiol*. 2003 Apr 16;41(8):1358-63.
  63. Weidnerpass E, Adami HO, Baron JA et al. Risk of endometrial cancer following estrogen replacement with and without progestins. *J Natl Cancer Inst*. 1999 Jul 7;91(13):1131-7.
  64. Wolf AS. Progestagene sind nicht Progesteron. In: Römmler A, Wolf AS. (Hrsg.) *Anti-Aging Sprechstunde, Teil 1: Leitfaden für Einsteiger*. Congress Compact Verlag, Berlin, 2002; 95-102.